Top Markets
Coin of the day
Invivyd, Inc. Invivyd, Inc.

Invivyd, Inc.

IVVD
株式のランク #17261
Adagio Therapeutics, Inc., a biopharmaceutical firm in its clinical development... Adagio Therapeutics, Inc., a biopharmaceutical firm in its clinical development phase, operates within the United States, specializing in the discovery, progression, and marketing of antibody-derived solutions for infectious diseases. The company's leading drug candidate, ADG20 (adintrevimab), is a neutralizing antibody currently undergoing Phase 3 clinical investigation for both the management and prevention of coronavirus disease. Adagio Therapeutics maintains collaborative agreements with Adimab, LLC to facilitate the identification and enhancement of its exclusive antibodies. Furthermore, it partners with the Scripps Research Institute to conduct studies aimed at uncovering potential vaccine solutions for the prophylaxis, detection, or therapy of influenza or beta coronaviruses. Incorporated in 2020, the company's base of operations is in Waltham, Massachusetts.
株価
$0.8502
最終同期: 2026-09-01
時価総額
$250.47M
変化(1日)
-10.96%
変化(1年)
-17.46%
US
取引 Invivyd, Inc. (IVVD)

カテゴリー

Invivyd, Inc.(IVVD)のP/B比率
2026 時点のP/B比率 TTM: 0
Invivyd, Inc. の最新の財務報告および株価によると、現在のP/B比率(TTM)は 0 です。2026 年末時点でのP/B比率は 0 でした。
Invivyd, Inc. の P/B 比率の履歴(2026 ~ 2026)
各年末時点のP/B比率
P/B比率 変化
提供された日付のデータは十分ではありません。
同業他社のP/B比率
企業 P/B比率 P/B比率の差
6.828 -
US
7.5116 -
NL
8.2199 -
US
3.9942 -
AU
- -
CH